The
immunologically mediated b -cell
destruction of Type I Diabetes
is a slow process indicated
by the appearance of antibodies
against pancreatic islet cells,
insulin, glutamic acid decarbonylase
(GAD) and islet cell antigen
512 (ICA512).
Anti-Islet
Cell Antibodies
Antibodies
to the pancreatic islet cells
of Langerhans occur almost exclusively
in type I diabetes and rarely,
if ever, in type II diabetes.
Islet cell antibodies may occur
years before clinical symptoms
of diabetes and may eventually
disappear after the clinical
onset of type 1 diabetes. The
ImmuGlo™ Islet Cell IFA
Positive Control, which is included
in the Anti-Islet Cell kit is
standardised against the JDF
(Juvenile Diabetes Foundation)
reference preparation. This
feature provides a useful standard
for inter-laboratory comparison
of results and establishes objective
performance criteria.
Anti-ICA/512
Antibodies
Anti-ICA
512 antibodies are found in
80% of recent onset IDDM patients
and are strongly associated
with a rapid progression to
overt IDDM.
